HRTX News and Press, Heron Therapeutics Inc. From 10/04/19

Major benchmarks generally did well on Friday, as investors were pleased to get good news on the employment front to help counter some of the weaker readings in economic data in recent days. After such a significant pullback in stocks, many market participants also seemed ready to have at least ...

The following slide deck was published by Heron Therapeutics, Inc. in conjunction with this Read more ...

Arbutus Biopharma (NASDAQ: ABUS )  -25%  after a decision to  stop development of AB-506. More news on: Arbutus Biopharma Corporation, Ovid Therapeutics Inc., PDS Biotechnology Corporation, Stocks on the move, Read more ...

Heron Therapeutics (NASDAQ: HRTX ) prices its public offering of 8.57M common shares at $17.50/share, for gross proceeds of ~$150M. More news on: Heron Therapeutics, Inc., Healthcare stocks news, Read more ...

SAN DIEGO , Oct. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. ("Heron") (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced...

A lion doesn't concern itself with the opinion of sheep .”― George R.R. Martin, A Game of Thrones It has been a trying ten days or so for biotech investors. The SPDR Biotech ETF ( XBI ) was down over seven percent last week and is down again this week. Some biotech compani...

Heron Therapeutics (NASDAQ: HRTX ) is 4.5% lower after hours following its announcement of a proposed public offering of common stock . More news on: Heron Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

SAN DIEGO , Oct. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. ("Heron") (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced...

SAN DIEGO , Oct. 2, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced positive ...

SAN DIEGO , Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced...